Denmark· DK-28105868716
Rolufta
A umeclidinium bromide product containing umeclidinium bromide, registered in Denmark by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Umeclidinium bromide is registered in 12 of 19 countries.
Countries holding a registration under ATC R03BB07 (umeclidinium bromide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Umeclidinium bromide · ATC R03BB07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of umeclidinium bromide costs, country by country.
Normalised to the WHO defined daily dose (55 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Umeclidinium bromide · price per daily dose (55 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$1.57
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Umeclidinium bromide
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Denmark (DK)
- ATC code
- R03BB07
- ATC class
- Umeclidinium bromide
- Defined daily dose
- 55 mcg, Inhal
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105868716
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
114 interactions on record for umeclidinium bromide.
Graded by severity as the source publishes them — 113 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Umeclidinium bromide · interactions on record
114 records
- 113 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R03BB07
Umeclidinium bromide, as other registers publish it.
- SwitzerlandIncruse Ellipta
- FinlandIncruse ElliptaParanova Oy
- FinlandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- IcelandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- PolandIncruse ElliptaGlaxoSmithKline (Ireland) Limited
- SwitzerlandIncruse Ellipta
- DenmarkIncruse ElliptaGlaxosmithkline Trading Services Limited
- NorwayIncruse ElliptaGlaxoSmithKline Trading Services Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/32e10175-eeef-4eb8-930a-02df1f2661fb GET /v1/drugs/32e10175-eeef-4eb8-930a-02df1f2661fb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "inhalationspulver, afdelt",
"source": "dkma",
"strength": "55 mikrogram",
"auth_role": "MOD",
"dk_drugid": "28105868716",
"substance": "Umeclidinium bromide",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "42814"
}See everything about umeclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.